Novel therapies in the treatment of spondyloarthritis

Bibliography

• BAETEN D, DEMETTER P, CUVELIER C et al.: Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann. Rheum. Dis. (2000) 59:945–953.
   PubMed Web of Science ®Google Scholar
• REECE RJ, CANETE JD, PARSONS WJ, EMERY P, VEALE DJ: Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritic Rheum. (1999) 42:1481–1484.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D, BELLAMY N, CALIN A et al.: Preliminary core sets for endpoints in ankylosing spondylitis. I Rheumatol (1997) 24:2225–222.
   Google Scholar
• WARD MM: Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. (2002) 46:223–231.
   PubMed Web of Science ®Google Scholar
• •This manuscript highlights the substantial costs associated with work disability and functional loss consequent to AS.
   Google Scholar
• GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GASFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol (1994) 21:2286–2291.
   PubMed Web of Science ®Google Scholar
• ANDERSON JJ, BARON G, VAN DER HEIJDE D et al.: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. (2001) 44:1876–1886.
   Google Scholar
• ••This report describes a composite responsecriterion developed for AS.
   Google Scholar
• MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy. Arthritic Rheum. (1998) 41:694–700.
   PubMed Web of Science ®Google Scholar
• LALOUX L, VOISIN M-C, ALLAIN J et al.: Immunohistological study of entheses in spondyloathropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (2001) 60:316–321.
   PubMed Web of Science ®Google Scholar
• BROWN MA, LAVAL SH, BROPHY S, CALIN A: Recurrence risk modeling of the genetic susceptibility to ankylosing spondylitis. Ann. Rheum. Dis (2000) 59:268–270.
   Web of Science ®Google Scholar
• HAMMER RE, MAIKA SD, RICHARDSON JA, TANG JP, TAUROG JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell (1990) 63:1099–1112.
   PubMed Web of Science ®Google Scholar
• MIELANTS H, VEYS EM, GOEMAERE S, GOETHALS K, CUVELIER C, DE VOS M: Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J. Rheumatol (1991) 18:1542–1551.
   Web of Science ®Google Scholar
• ZHANG Y, GUERASSIMOV A, LEROUX JY et al.: Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of T and B cell epitopes.j Clin. Invest. (1998) 101:1678–1686.
   Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499–505.
   PubMed Web of Science ®Google Scholar
• •First description of TNF-a expression in the sacroiliac joint of patients with AS.
   Google Scholar
• DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: What is the optimum duration of a clinical study? One year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (1999) 38:235–244.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, BEHIER JM, JOLCINE I et al: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritic Rheum. (2001) 44:180–185.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondyloarthropathy. Arthritic Rheum. (1995) 38:618–627.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritic Rheum. (1996) 39:2004–2012.
   PubMed Web of Science ®Google Scholar
• MACKAY K, MACK C, BROPHY S, CALIN A: The Bath Ankylosing Spondylitis Radiology Index (BASRI). Arthritic Rheum. (1998) 41:2263–2270.
   PubMed Web of Science ®Google Scholar
• DAWES P: Stoke ankylosing spondylitis score. Rheumatol (1999) 26:993–997.
   Web of Science ®Google Scholar
• VERSTRAETE KL, DE DEENE Y, ROELS H, DIERICK A, UYTTENDAELE D, KKUNNEN M: Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging - parametric 'first-pass' images depict tissue vascularization and perfusion. Radiology (1994) 192:835–843.
   PubMed Web of Science ®Google Scholar
• RUDWALEIT M, SIEGERT S, YIN Z et al:Low T cell production of TNFa and IFNy in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF -308 gene polymorphism. Ann. Rheum. Dis. (2000) 60:36–42.
   Web of Science ®Google Scholar
• CREW MD, EFFROS RB, WALFORD RL, ZELLER E, CHEROUTRE H, BRAHN E: Transgenic mice expressing a truncated Peromyscus leucopusTNF-a gene manifest an arthritis resembling ankylosing spondylitis. Interferon Cytokine Res (1998) 18:219–225.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59:428–433.
   PubMed Web of Science ®Google Scholar
• •A preliminary report describing rapid onset of anti-inflammatory activity in most subsets of SpA.
   Google Scholar
• KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: TNFa blockade with infliximab in patients with active spondyloarthropathy: Follow up of one year maintenance regime. Arthritis Rheum. (2001) 44:S90.
   Google Scholar
• BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Thl cytokine production in spondyloarthropathy is restored by anti-TNFa. Ann. Rheum. Dis. (2001) 60:750–755.
   Google Scholar
• BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al. Immunomodulatory effects of anti-tumor necrosis factor a therapy on synovium in spondyloarthropathy: Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. (2001) 44:186–195.
   Google Scholar
• •This report suggests that infliximab therapy may possess disease-modifying properties.
   Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. (2002) 46:755–765.
   PubMed Web of Science ®Google Scholar
• ••This report describes major improvement in
   Google Scholar
• SpA patients receiving infliximab in a randomised, double-blinded, placebo-controlled trial.
   Google Scholar
• BRANDT J, HAEBEL H, CORNELY D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum. (2000) 43:1346–1352.
   PubMed Web of Science ®Google Scholar
• BRANDT J, BRAUN J, SIEPER J: Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum. (2001) 44:2936–2937.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING Jet al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet (2002) 359:1187–1193.
   Google Scholar
• ••The first double-blind trial of an anti-TNF-a agent in AS refractory to NSAIDs. Major clinical responses were observed in 50% of patients.
   Google Scholar
• STONE M, SALONEN D, LAX M et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. Rheumatol (2001) 28:1605–1614.
   Web of Science ®Google Scholar
• •This report indicates that even patients with advanced disease have significant responses although less than in those with short disease duration.
   Google Scholar
• BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in severe refractory ankylosing spondylitis (AS) results of a 6 month follow-up open-label study. Arthritis Rheum. (2001) 44\(Suppl. 9):589.
   Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. Rheumatol (2002) 29:959–967.
   Web of Science ®Google Scholar
• ANTONI C, DECHANT C, OGILVIE A et al. Successful treatment of psoriatic arthritis with infliximab in an MRI-controlled study. J. Rheumatol (2000) 27\(Suppl. 59):24.
   Google Scholar
• BRANDT J, HAIBEL H, REDDIG J, SIEPERJ, BRAUN J: Successful sshort term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-a monoclonal antibody infliximab. Rheumatol (2002) 29:118–122.
   Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• ••This is the first controlled single-centre trialdemonstrating efficacy for an anti-TNF-a agent in psoriatic arthritis and psoriasis. Efficacy data is remarkable with no significant toxicity in this 12-week trial.
   Google Scholar
• MEASE PJ, GOFFE BS, VANDERSTOEP A, BURGE DJ: Etanercept in patients with psoriatic arthritis and psoriasis. Arthritic Rheum. (2000) 43 (Suppl.):S403.
   Google Scholar
• MEASE PJ, KIVITZ A, BURCH F et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept: results of a Phase III multicentre clinical trial. Arthritic Rheum. (2001) 44(Suppl.):S90
   Google Scholar
• •The preliminary findings in this Phase III multi-centre trial confirm the efficacy noted with etanercept in psoriatic arthritis although fewer patients achieved major clinical responses than in the single-centre study.
   Google Scholar
• GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl. J. Med. (2002) 346:1349–1356.
   PubMed Web of Science ®Google Scholar
• •First report on the use of etanercept in AS in a placebo-controlled single-centre trial. Significant efficacy was noted in 80% of patients with minimal toxicity.
   Google Scholar
• GORMAN JD, SACKS KE, DAVIS JC: An open label trial of etanercept in the treatment of ankylosing spondylitis. Arthritic Rheum. (2001) 44(Suppl.):S91.
   Google Scholar
• MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. Arthritic Rheum. (2001) 44:2112–2117.
   PubMed Web of Science ®Google Scholar
• •A detailed MRI evaluation of entheseal sites is described before and after therapy with etanercept. Both clinical and radiological remission of inflammation in - 90% of patients suggests that etanercept may possess disease-modifying properties in SpA.
   Google Scholar
• BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. (1999) 42:580–581.
   PubMed Web of Science ®Google Scholar
• BREBAN M, DOUGADOS M: The efficacy of thalidomide in severe refractory seronegative spondyloarthropathy: reply to Lee et al Arthitis Rheum. (2001) 44:2457–2458.
   Google Scholar
• HUANG F, GU J, ZHAO W et al.: Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis. Arthritis Rheum. (2001) 44\(Suppl. 9):5275.
   Google Scholar
• LIANG GC, BARR WG: Leflunomide for psoriatic arthritis and psoriasis. Arthritis Rheum. (1999) 42 (Suppl.):S371.
   Google Scholar
• DINANT HJ, VAN KUIJK AWR, GOEDKOOP AY et al.: Alefacept (LFA3-IgG1 fusion protein) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis. Arthritis Rheum. (2002) 44(Suppl.):S91.
   Google Scholar
• BARBIER A, BRELIERE JC, REMANDET B, RONCUCCI R: Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann. Rheum. Dis. (1986) 45:67–74.
   PubMed Web of Science ®Google Scholar
• FRANCIS MD, HOVANCIK K, BOYCE RW: NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int. J. Tissue Reactions (1989) 11:239–252.
   PubMedGoogle Scholar
• PENNANEN N, LAPINJOKI S, URTI A, MONKKONEN J: Effect of liposomal and free bisphosphonates on the IL-13, IL-6 and TNF.secretion from RAW 264 cells M vitro. Pharm. Res. (1995) 12:916–922.
   PubMed Web of Science ®Google Scholar
• SANSONI P, PASSERI G, FAGNONI F et al.: Inhibition of antigen-presenting cell function by alendronate in vitro. J. Bone Miner Res. (1995) 10:1719–1725.
   PubMed Web of Science ®Google Scholar
• GRATACOS J, COLLADO A, PONS F etal.: Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow up study. Arthritis Rheum. (1999) 42:2319–2324.
   Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LECLERCQ S, SKEITH K, YAN A, RUSSELL AS: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. Rheumatol. (1998) 25:714–717.
   Web of Science ®Google Scholar
• MAKSYMOWYCH WP, LAMBERT R, JHANGRI GS et al: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J. Rheumatol. (2001) 28:144–155.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD A et al.: A six-month randomized, controlled, double-blinded, dose response comparison of intravenous pamidronate (60mg versus 10 mg) in the treatment of NSAID-refractory ankylosing spondylitis. Arthritis Rheum. (2002) 46:766–782.
   PubMed Web of Science ®Google Scholar
• •This report describes significant efficacy by 6 months with monthly administration of 60 mg iv. pamidronate with only minor adverse events in patients with NSAID-refractory AS.
   Google Scholar